Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit

Matthew Mei,[1] Mehdi Hamadani,[2] Kwang W. Ahn,[3,4] Yue Chen,[4] Mohamed A. Kharfan-Dabaja,[5] Craig Sauter[2] and Alex F. Herrera[1]

[1]Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; [2]BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; [3]Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI; [4]Center for International Blood and Marrow Transplant Research, Milwaukee, WI and [5]Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA

Correspondence: MEHDI HAMADANI - mhamadani@mcw.edu

Supplemental Table 1. Variables tested in Cox proportional hazards regression model

<u>Main effect:</u>
- **CR vs. PR**

<u>Patient-related</u>:
- **Age at transplant, Continuous & by age group: decades**
- **Race – White vs. African American vs. Others vs. Missing**
- **Karnofsky performance status at transplant: 90-100 vs. < 90 vs. missing**

<u>Disease-related</u>:
- **Interval between diagnosis and HCT**
- **Conditioning: BEAM vs. R-BEAM**
- **Year of transplant**
- **Early chemoimmunotherapy failure: No vs. yes**

CR: complete remission; PR: partial remission; BEAM: carmustine, etoposide, cytarabine, melphalan; R-BEAM: rituximab + BEAM

Supplemental Table 2. Multivariable regression analysis of outcomes

Non-relapse mortality	N	HR (95% CI)	p-value
CR	154	1	
PR	131	1.09 (0.58-2.06)	0.80
Progression/relapse	**N**	**HR (95% CI)**	**p-value**
CR	154	1	
PR	131	1.59 (1.13-2.24)	0.008
Progression free survival	**N**	**HR (95% CI)**	**p-value**
CR	154	1	
PR	131	1.46 (1.08-1.97)	0.01
Overall Survival	**N**	**HR (95% CI)**	**p-value**
CR	154	1	
PR	131	1.55 (1.12-2.15)	0.009

CR: complete remission; PR: partial remission

Supplemental Table 3. Regimens used in the 3L setting

ICE +/- rituximab	101
Gemcitabine/platinum +/- rituximab	11
ESHAP/DHAP +/- rituximab	26
Hyper-CVAD-like +/- rituximab	16

ICE: ifosfamide, carboplatin, etoposide; ESHAP: etoposide, methylprednisolone, cytarabine, cisplatin; DHAP: dexamethasone, cytarabine, cisplatin; Hyper-CVAD: cyclophosphamide, vincristine, adriamycin, dexamethasone